We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 29

Controversy surrounds the use of the term "natural" with genetically modified organisms (GMOs)
  • Hodgson Russ LLP
  • USA
  • September 26 2013

Recently, courts weighed in on the controversy over using the very used and popular claim "all natural" on new U.S. food products containing


FDA issues draft guidance on medical device reporting for manufacturers
  • Hodgson Russ LLP
  • USA
  • September 3 2013

On July 9, 2013, the FDA issued a draft guidance document titled "Medical Device Reporting for Manufacturers." Written in a question and answer


The far reach of California Proposition 65
  • Hodgson Russ LLP
  • USA
  • March 22 2013

In 1986, California voters approved an initiative to address their growing concerns with exposure to toxic chemicals. That initiative became the Safe


FDA's final rule for combination products
  • Hodgson Russ LLP
  • USA
  • January 29 2013

On January 22, 2013, the Food and Drug Administration (FDA) issued a final rule on current good manufacturing practice (CGMP) requirements applicable


Another victory for FDA, bigger warning for regulated industry
  • Hodgson Russ LLP
  • USA
  • July 12 2012

On July 2, British drug maker GlaxoSmithKline agreed to plead guilty and pay a $3 billion fine for its off-label marketing of three drugs and for its failure to comply with the FDA’s post-marketing reporting requirements for one of its drugs


Device guidance update
  • Hodgson Russ LLP
  • USA
  • July 6 2012

Those of us practicing law or working in device regulatory compliance in the United States are not alone in our quest to better understand the mood and direction of the Centers for Device and Radiological Health (CDRH


IOM report on food and medical product safety from foreign sources highlights large-scale shortcomings
  • Hodgson Russ LLP
  • USA
  • April 24 2012

The Institute of Medicine (IOM) Committee on Strengthening Core Elements of Regulatory Systems in Developing Countries recently issued a report entitled “Ensuring Safe Foods and Medical Products Through Stronger Regulatory Systems Abroad.”


Requests for information: Section 513(g) submissions have pros and cons
  • Hodgson Russ LLP
  • USA
  • April 13 2012

The FDA continues to push its regulatory agenda and priorities primarily through guidance rather than notice and comment rulemaking


Labeling, advertising, and promotion of medical products
  • Hodgson Russ LLP
  • USA
  • April 9 2012

Proper labeling of products regulated by the FDA is extremely crucial


FDA and FTC issue warnings for illegal homeopathic weight-loss remedies
  • Hodgson Russ LLP
  • USA
  • December 20 2011

At the end of November, the Food and Drug Administration (FDA) issued warning letters to seven companies marketing diet products containing human chorionic gonadotropin (hCG